EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics

Rima Nabbout iD, Joseph Sullivan iD, Stéphane Auvin iD, J Helen Cross iD, Orrin Devinsky iD, Antonio Gil-Nagel iD, Renzo Guerrini, Kelly G Knupp iD, M Scott Perry iD, Rocío Sánchez-Carpintero iD, An-Sofie Schoonjans iD, Ingrid E Scheffer und 9 weitere

Epilepsia Open · 2026

DOI: 10.1002/epi4.70340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2026. Verfasst von Rima Nabbout und 20 weiteren Autor:innen. Beteiligte Einrichtung: Reference Centre for Rare Epilepsies, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Member of the European Reference Network (ERN) EpiCARE, Pa…. Hauptthemen laut MEDLINE: Fenfluramine, Epilepsies, Myoclonic, Anticonvulsants. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) stratified by age, number of previously attempted antiseizure medications (ASMs), and SCN1A pathogenic variant status.

Methods

In this post hoc analysis, data from three randomized controlled trials (RCTs) in patients with DS (2–18 years) were pooled and stratified by age (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenfluramineEpilepsies, MyoclonicAnticonvulsantsHumansChildChild, PreschoolAdolescentNAV1.1 Voltage-Gated Sodium ChannelFemaleMaleRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

SCN1Aconvulsive seizure frequencydevelopmental and epileptic encephalopathyglobal functioningpediatricssafety and efficacy studies

Substanzen

FenfluramineAnticonvulsantsNAV1.1 Voltage-Gated Sodium ChannelSCN1A protein, human

Autor:innen und Institutionen

  • Reference Centre for Rare Epilepsies, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Member of the European Reference Network (ERN) EpiCARE, Paris, France.
  • Institut Imagine, INSERM 1163, Université Paris Cité, Paris, France.
  • University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital, San Francisco, California, USA.
  • AP-HP, Reference Center for Rare Epilepsies, Member of ERN EpiCARE, Hôpital Universitaire Robert Debré, Paris, France.
  • Institut Hospitalo-Universitaire Robert-Debré du Cerveau de l'Enfant, Paris, France.
  • INSERM NeuroDiderot, Université Paris-Cité, Paris, France.

ORCID-Profile: Rima Nabbout, Joseph Sullivan, Stéphane Auvin, J Helen Cross, Orrin Devinsky, Antonio Gil-Nagel, Kelly G Knupp, M Scott Perry, Rocío Sánchez-Carpintero, An-Sofie Schoonjans, Nicola Specchio, Adam Strzelczyk, James Wheless, Elaine C Wirrell, Amélie Lothe, Lieven Lagae

Zitieren

APA

Nabbout, R., Sullivan, J., Auvin, S., Cross, J. H., Devinsky, O., Gil-Nagel, A., Guerrini, R., Knupp, K. G., Perry, M. S., Sánchez-Carpintero, R., Schoonjans, A. S., Scheffer, I. E., Specchio, N., Strzelczyk, A., Wheless, J., Wirrell, E. C., Morita, D., Healy, P., Langlois, M., …, & Lagae, L. (2026). Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics. Epilepsia Open. https://doi.org/10.1002/epi4.70340

Vancouver

Nabbout R, Sullivan J, Auvin S, Cross JH, Devinsky O, Gil-Nagel A, et al. Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics. Epilepsia Open. 2026. doi:10.1002/epi4.70340

BibTeX
@article{Nabbout2026,
  author = {Nabbout, Rima and Sullivan, Joseph and Auvin, Stéphane and Cross, J Helen and Devinsky, Orrin and Gil-Nagel, Antonio and Guerrini, Renzo and Knupp, Kelly G and Perry, M Scott and Sánchez-Carpintero, Rocío and Schoonjans, An-Sofie and Scheffer, Ingrid E and Specchio, Nicola and Strzelczyk, Adam and Wheless, James and Wirrell, Elaine C and Morita, Diego and Healy, Patrick and Langlois, Mélanie and Lothe, Amélie and Lagae, Lieven},
  title = {Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics},
  journal = {Epilepsia Open},
  year = {2026},
  doi = {10.1002/epi4.70340}
}
Kostenlos starten →